UCB (UCBJY) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UCBJY UCB SA UCBJY
89 GF Score
Price $119.58
GF Value $143.29
Valuation Modestly Undervalued
View Full Analysis

What is UCB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


UCB  (OTCPK:UCBJY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


UCB Cyclically Adjusted PS Ratio Related Terms


UCB Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for UCB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Cyclically Adjusted PS Ratio Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.85 2.43 2.66 5.80 7.70

UCB Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.43 5.75 5.62 7.64 7.81

UCBJY vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, UCB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UCB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where UCB's Cyclically Adjusted PS Ratio falls into.


UCBJY
89GF Score
UCB SA UCBJY
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

UCB's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, UCB's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=22.495/135.0800*135.0800
=22.495

Current CPI (Dec25) = 135.0800.

UCB Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 12.177 102.614 16.030
201712 13.569 104.804 17.489
201812 14.496 107.252 18.257
201912 14.686 108.065 18.357
202012 15.690 108.511 19.532
202112 17.583 114.705 20.706
202212 14.880 126.578 15.880
202312 14.545 128.292 15.315
202412 17.103 132.346 17.456
202512 22.495 135.080 22.495

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is UCB (UCBJY) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be undervalued. The current stock price of $119.58 is trading 16.5% below its estimated GF Value™ of $143.29. GuruFocus considers UCB to be Modestly Undervalued.

Key valuation signals for UCBJY:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $143.29 vs. price of $119.58 (16.5% below fair value)
  • GF Score™: 89/100

No single metric tells the full story. See the UCBJY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
89GF Score

Get the complete analysis for UCBJY

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$119.58
Price
$143.29
GF Value